0001005201-19-000021.txt : 20190214 0001005201-19-000021.hdr.sgml : 20190214 20190214162006 ACCESSION NUMBER: 0001005201-19-000021 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190212 FILED AS OF DATE: 20190214 DATE AS OF CHANGE: 20190214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Peisert Daniel A. CENTRAL INDEX KEY: 0001758376 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-13111 FILM NUMBER: 19606669 MAIL ADDRESS: STREET 1: C/O ASSERTIO THERAPEUTICS, INC. STREET 2: 100 SOUTH SAUNDERS ROAD, SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Assertio Therapeutics, Inc CENTRAL INDEX KEY: 0001005201 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943229046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 SOUTH SAUNDERS RD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 BUSINESS PHONE: (224) 419-7106 MAIL ADDRESS: STREET 1: 100 SOUTH SAUNDERS RD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 FORMER COMPANY: FORMER CONFORMED NAME: DEPOMED INC DATE OF NAME CHANGE: 19970408 4 1 wf-form4_155017919253942.xml FORM 4 X0306 4 2019-02-12 0 0001005201 Assertio Therapeutics, Inc ASRT 0001758376 Peisert Daniel A. ASSERTIO THERAPEUTICS, INC. 100 SOUTH SAUNDERS ROAD, SUITE 300 LAKE FOREST IL 60045 0 1 0 0 SVP and CFO Restricted Stock Units 2019-02-12 4 A 0 82763 0 A 2022-02-12 Common Stock 82763.0 82763 D Performance Shares 2019-02-12 4 A 0 4087 0 A Common Stock 4087.0 4087 D Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock. One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022, assuming continued employment through the applicable vesting date. The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. Represents the current tranche of performance shares earned under the 2018 performance share award as of February 12, 2019, at which date the Compensation Committee certified the extent to which the current tranche performance criteria were met. Each earned performance share represents the contingent right to receive one share of common stock. Each performance share will convert into one share of common stock upon vesting and settlement in the first quarter of 2021. /s/ Erin R. McQuade, attorney in fact 2019-02-14